(Translated by https://www.hiragana.jp/)
奥那妥珠单抗 - 维基百科，自由的百科全书 跳とべ转到内容ないよう

奥おく那な妥珠单抗

维基百科ひゃっか，自由じゆう的てき百科ひゃっか全ぜん书
奥おく那な妥珠单抗
单克隆たかし抗体こうたい
种类Fab片かた段だん（英えい语：Fab fragment）
目標もくひょう散ち射い因子いんし受体激げき酶
臨床りんしょう資料しりょう
ATC碼
  • 未み分配ぶんぱい
识别信しん息いき
CAS号ごう1133766-06-9  ☒N
ChemSpider
  • none
UNII
化学かがく信しん息いき
化学かがく式しきC4422H6820N1168O1363S31
摩ま尔质量りょう99,147.88 g·mol−1

奥おく那な妥珠单抗（INN：onartuzumab）是ぜ一いち种人ひと源げん化か单克隆たかし抗体こうたい，设计用よう于治疗晚期き非ひ小しょう细胞肺癌はいがん。[1][2][3]

奥おく那な妥珠单抗由ゆかり基もと因よし泰たい克かつ公司こうし开发，正せい在ざい进行临床试验。[4][5][6][7]

参考さんこう资料

[编辑]
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab (PDF). American Medical Association. [2024-03-15]. （原始げんし内容ないよう存そん档 (PDF)于2015-07-23）. 
  2. ^ Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res. December 2012, 1 (4): 238–53. PMC 4367550 可免费查阅. PMID 25806189. doi:10.3978/j.issn.2218-6751.2012.10.08. 
  3. ^ Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Onartuzumab in lung cancer: the fall of Icarus?. Expert Rev Anticancer Ther. May 2015, 15 (5): 487–9. PMID 25818471. doi:10.1586/14737140.2015.1031219 可免费查阅. 
  4. ^ Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. J Clin Pharmacol. November 2013, 53 (11): 1103–11. PMID 23922054. S2CID 206059437. doi:10.1002/jcph.148. 
  5. ^ Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. Clin Lung Cancer. November 2012, 13 (6): 500–4. PMID 23063071. doi:10.1016/j.cllc.2012.05.009. 
  6. ^ Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. November 2013, 31 (32): 4105–14. PMC 4878106 可免费查阅. PMID 24101053. doi:10.1200/JCO.2012.47.4189. 
  7. ^ Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer. Invest New Drugs. June 2015, 33 (3): 632–40. PMID 25777467. S2CID 20118425. doi:10.1007/s10637-015-0227-5. 
检索自じ“https://zh.wikipedia.org/w/index.php?title=奥おく那な妥珠单抗&oldid=83747228”